- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions

European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
Pharmaceuticals - Community Register
Community register of medicinal products for human use |
AUTHORISED |
Product information |
| Invented name: | Plenadren
|
| Auth. number : | EU/1/11/715 |
| Active substance : | hydrocortisone |
| Orphan market exclusivity for "Treatment of adrenal insufficiency" (based on designation EU/3/06/372) started on 14/11/2011 10 years of market exclusivity This orphan market exclusivity will expire on 14/11/2021 | |
| ATC: | Anatomical main group: H - Systemic hormonal prep, excluding sex hormones Therapeutic subgroup: H02 - Corticosteroids for systemic use Pharmacological subgroup: H02A - Corticosteroids for systemic use, plain Chemical subgroup: H02AB - Glucocorticoids Chemical substance: H02AB09 - Hydrocortisone (See WHO ATC Index) |
| Indication: | Treatment of adrenal insufficiency in adults. |
| Marketing Authorisation Holder: | Shire Services BVBA
rue Montoyer 47, 1000 Bruxelles, Belgique / Montoyerstraat 47, 1000 Brussel, België |
|
EPAR and active package presentations | |
Package presentations | |
|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information". Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register. |
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 14/11/2011 | Centralised - Authorisation | EMEA/H/C/2185 | (2011)8058 of 03/11/2011 | |||
| 28/03/2012 | Centralised - Transfer Marketing Authorisation Holder | EMEA/H/C/2185 | (2012)2170 of 26/03/2012 | |||
| 31/05/2012 | Centralised - Variation | EMEA/H/C/2185/IB/2 | ||||
| Updated with Decision(2012)7951 of 29/10/2012 | ||||||
| 05/06/2012 | Centralised - Variation (refusal) | EMEA/H/C/2185/IA/3 | ||||
| 06/11/2012 | Centralised - Variation | (2012)7951 of 29/10/2012 | ||||
| 07/11/2012 | Centralised - Variation | EMEA/H/C/2185/IAin/8 | ||||
| Updated with Decision(2013)8336 of 20/11/2013 | ||||||
| 10/07/2013 | Centralised - Variation | EMEA/H/C/2185/IB/11/G | ||||
| Updated with Decision(2013)8336 of 20/11/2013 | ||||||
| 21/11/2013 | Centralised - Yearly update | (2013)8336 of 20/11/2013 | ||||
| 03/12/2015 | Centralised - Variation | EMEA/H/C/2185/IG/603/G | ||||
| Updated with Decision(2016)2949 of 11/05/2016 | ||||||
| 13/05/2016 | Centralised - Yearly update | (2016)2949 of 11/05/2016 | ||||
| 26/05/2016 | Centralised - Variation | EMEA/H/C/2185/II/21 | ||||
| Updated with Decision(2016)5263 of 08/08/2016 | ||||||
| 10/08/2016 | Centralised - Renewal | EMEA/H/C/2185/R/20 | (2016)5263 of 08/08/2016 | |||
| 13/10/2016 | Centralised - Variation | EMEA/H/C/2185/II/22 | ||||


